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Background/Aims: Interferon beta (IFN-β) has been 
shown to have antiviral activity, and thus could be 
useful in treating viral infections. Therefore, we com-
pared the efficacy and safety of recombinant IFN-β 
(IFN-β-1a) plus oral ribavirin versus interferon alpha 
(IFN-α) plus ribavirin therapy for the treatment of 
chronic hepatitis C (HCV). Methods: Twenty treat-
ment-naïve patients were randomized into two 
equal-sized treatment groups. Both IFN-β-1a (44μg) 
and IFN-α (3 MIU) were given subcutaneously three 
times a week, while ribavirin was given orally at 
1,000-1,200 mg/day. Patients were treated for 24 
weeks and followed for an additional 24 weeks. 
Results: After 24 weeks of treatment, six (60%) and 
four patients (40%) in the IFN-β-1a group and IFN-α 
groups, respectively, achieved viral clearance. The 
sustained virological response (SVR) at the end of the 
observation period was similar in both groups (40%). 
However, the baseline viral load was significantly 
higher (p=0.034) in the IFN-β-1a group than in the 
IFN-α group, and there were more HCV genotype 1 
patients in the IFN-β-1a group (eight versus seven). 
The IFN-β-1a group was associated with similar ad-
verse events in terms of frequency and severity. 
Conclusions: The SVR rate and safety profile were 
similar for the combination of IFN-β-1a and ribavirin 
and that of IFN-α and ribavirin. (Gut and Liver 
2009;3:20-25)
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INTRODUCTION
  Since the isolation of hepatitis C virus (HCV) genome 
back in 1989 and the establishment of consequences of 
the infection, treatment modalities have undergone sev-
eral changes over the last decade.1-4 From the early era 
when interferon alpha (IFN-α) monotherapy was given at 
3 MIU for 24 week with a sustained virological response 
(SVR) rate of less than 10% to the current treatment of 
48-week pegylated IFN-α plus ribavirin combined where 
56% of SVR rate could be obtained, significant progresses 
have been achieved to counter this chronic infectious 
disease.5-7
  Despite this achievements, there remains a large cohort 
of patients who do not have their viruses cleared even af-
ter 48 weeks of treatment with pegylated IFN-α plus rib-
avirin therapy. This includes approximately 50% of the 
difficult-to-treat HCV genotype 1 cohort and about 20% 
of the HCV genotype type 2 or 3 cohort.8 Re-treatment 
with similar regimen after the initial failure is not an op-
timal choice as the outcome is relatively poor.9,10 
Furthermore, the IFN-α based treatment is not without 
side effects. Patients often have to discontinue treatment 
due to intolerable side effects or reduce the treatment 
dosages to minimize such effects.11 Indeed, there is an ur-
gent need to investigate other treatment options to close 
the gaps on efficacies and safety profiles of the current 
regimens.
  Interferon beta (IFN-β) is classified under the same 
type I IFN family with IFN-α since both molecules share 
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a common cell surface receptor.12,13 Due to its antiviral 
activities, natural IFN-β produced by fibroblast cells has 
been used extensively in Japan for the treatment of HCV 
infection.14-17 Unfortunately, the intravenous admin-
istration route of the current natural IFN-β did not offer 
the same convenience compared to the subcutaneous 
route used in the IFN-α administration. Hence, the us-
age of natural IFN-β has largely been confined to Japan.
  Recombinant IFN-β (IFN-β-1a), produced by mamma-
lian cells, has a similar structure and glycosylation as the 
naturally occurring IFN-β.18 Early study in HCV infection 
showed that it had similar antiviral properties as IFN-α 
monotherapy.19 Recently, it has been shown to be safe 
and efficacious when combined with ribavirin.20 Another 
recent report has highlighted its potential therapeutic 
properties in Chinese population.21 However, all of these 
studies had been performed without a comparative IFN-α 
treatment arm. 
  We had conducted a prospective, randomized, com-
parative pilot study with two arms consisting of IFN-β- 
1a plus ribavirin versus IFN-α plus ribavirin in Korean 
population to investigate the efficacy and safety of both 
combination therapies in the same clinical setting.
MATERIALS AND METHODS
1. Patients
  We included patients at the age 18 or above with 
chronic HCV infection confirmed by HCV-RNA reverse 
transcriptase-polymerase chain reaction (RT-PCR). 
Patients should have an elevated serum alanine amino-
transferase (ALT) with level between 1.5 times and 10 
times the upper limit of normal. All had adequate bone 
marrow reserve and organ function. 
  Patients were excluded if they had undergone previous 
treatment with an IFN, clinical evidence of liver cirrhosis 
defined by a Child-Pugh score of 7 and above, history of 
hepatic failure, other viral hepatitis, history of immuno-
logically mediated disease, chronic renal impairment, his-
tory of cancer.
2. Study design
  This was an open, randomized, comparative pilot study 
conducted in a gastroenterology unit of a university-affi-
liated hospital in Korea. The study was reviewed and ap-
proved by the hospital Ethics Committee. Each patient 
was provided with his/her written consent prior to the 
start of the study. 
  After confirmation of patient’s eligibility, he/she would 
be randomized to receive IFN-β-1a (RebifⓇ, Serono inter-
national, Geneva, Switzerland) plus ribavirin or IFN-α 
(Intermax-alphaⓇ, LG Biotech, Taejeon, Korea) plus 
ribavirin. IFN-β-1a at 44 mcg per dose and IFN-α at 3 
MIU per dose were given three times a week subcu-
taneously. Ribavirin was given orally twice a day with a 
total daily dosage of 1,000-1,200 mg depending on the 
weight of the patient. The treatment duration was 24 
weeks followed by a 24-week observation phase. 
However, at treatment week 12, patient who did not ach-
ieve a virological response, defined as a decrease of at 
least 2 log viral load from the baseline, was removed 
from the treatment but would be included in the 24-week 
observation phase. Sustained virological response (SVR) 
was defined as a viral clearance, measured by a qualitative 
HCV RNA assay, at both the end of treatment and end of 
observation phase.
  Baseline assessments included hematology, blood chem-
istry, HCV genotyping and serum HCV RNA measure-
ment. Virological responses were assessed at treatment 
week 12, treatment week 24 and end of the observation 
period using both qualitative and quantitative HCV RNA 
assays. Qualitative HCV RNA measurement was per-
formed using a polymerase chain reaction assay with pri-
mers specific for the 5’ untranslated region of the HCV 
genome (COBAS Amplicor, version 2.0; Roche 
Diagnostics, Branchburg, NJ, USA) with a lower sensi-
tivity of 50 IU/ml while the quantitative HCV RNA 
measurement was done using the COBAS Monitor 
Amplicor HCV 2.0 (Roche Diagnostics, Meylan, France) 
with a lower detection limit of 600 IU/mL. Safety was as-
sessed by monitoring the adverse events and changes in 
the laboratory parameters at each study visits
3. Statistical analysis
  Data from both groups were analyzed and presented in 
a descriptive manner in terms of percentages and ranges. 
The assessments of baseline characteristics were per-
formed for the total study population. HCV genotype and 
gender were assessed by Chi-square test. Baseline param-
eters, for example, ALT and HCV RNA levels were as-
sessed by the nonparametric test Mann-Whitney U-test. 
The two-tailed significance level was set at 5%.
RESULTS
1. Patient characteristics
  A total of 20 patients, 10 for each treatment group, 
were enrolled and completed the study between 
December 2003 and March 2005. One patient with geno-
type 1b from each arm was considered as a non-res-
ponder at treatment week 12. In the IFN-α group, anoth-
er patient decided to withdraw her consent after 8 weeks 
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Table 1. Baseline Characteristics of the Patients
Variables IFN-β-1a (n=10) IFN-α (n=10) p-value
HCV genotype, n 1.000
  1b  8 7
  2a/2c  2 3
Male sex, n  6 6 1.000
Age (years) 50.5 (34-67) 53.5 (30-67) 0.570
AFP (IU/mL) 5.76 (2.36-10.54) 4.86 (1.4-19.3) 0.762
TSH (mIU/mL) 1.82 (1.13-2.18) 1.71 (0.94-4.99) 0.982
ALT (IU/mL) 129 (62-172) 130 (60-291) 0.762
WBC (×10
3
/μL) 5.33 (3.17-8.60) 5.99 (4.50-10.41) 0.257
Neutrophils (×10
3
/μL) 2.83 (1.75-5.00) 3.21 (1.10-6.67) 0.450
Hemoglobin (g/dL) 14.0 (12.2-16.9) 13.8 (11.7-15.9) 0.762
Platelets (×10
3
/μL) 192 (102-361) 214 (107-290) 0.734
Creatinine (mg/dL)  1.0 (0.7-1.3)  0.9 (0.7-1.1) 0.538
HCV RNA (×10
3 
IU/mL) 552 (68-1,330) 149 (11-956) 0.034
Qualitative variables are expressed as the median (25th-75th percentile).
IFN-β, interferon beta; IFN-α, interferon-alpha; AFP, alpha-fetoprotein; TSH, thyroid-stimulating hormone; ALT, alanine ami-
notransferase; WBC, white blood cells; HCV, hepatitis C virus.
Table 2. Overall Virological Responses
IFN-β-1a IFN-α
Genotype
Total
Genotype
Total
1b 2a/2c 1b 2a/2c
n=8 (%) n=2 (%) n=10 (%) n=7 (%) n=3 (%) n=10 (%)
EVR 7 (87.5) 2 (100) 9 (90) 6 (85.7) 2 (66.7) 8 (80)
ETR 4 (50) 2 (100) 6 (60) 2 (28.6) 2 (66.7) 4 (40)
SVR 2 (25) 2 (100) 4 (40) 2 (28.6) 2 (66.7) 4 (40)
IFN-β, interferon beta; IFN-α, interferon-alpha; EVR, early virological response (treatment week 12); ETR, end-of-treatment 
response (treatment week 24); SVR, sustained virologic response (the 24-week observation phase).
of the treatment. In total, 19 patients completed the 
study with 17 completed the 24 weeks of treatment fol-
lowed by 24 weeks of observation.
  All baseline parameters, except viral load, were found to 
be similar between the two groups (Table 1). IFN-β-1a 
group had a significantly higher (p=0.034) viral load as 
compared to that in the IFN-α group. IFN-β-1a had one 
additional patient with HCV genotype 1 infection than 
IFN-α group.
2. Efficacy
  The early virological response (EVR, treatment week 
12), end-of-treatment response (ETR, treatment week 24) 
and sustained virological response (SVR, the 24-week ob-
servation phase) are similar between the 2 groups (Table 
2). Nine out of 10 patients and 8 out of 10 patients had 
an EVR in the IFN-β-1a and IFN-α group respectively. 
The ETR was lower for both groups as compared to the 
EVR. At the end of the study, SVR was obtained in 4 out 
of 10 patients (40%) in both groups. Especially, the SVR 
was lower for patients with genotype 1b as compared to 
that with the genotype 2a/2c.
  By categorizing the virological response in terms of vi-
ral load, those greater than 400,000 IU/mL, none of the 2 
patients in the IFN-α group showed any virological re-
sponse in the 3 time points measured. In the IFN-β-1a 
group, 3 out of 7 patients achieved ETR though only one 
patient eventually achieved SVR (Table 3).
3. Safety and tolerability
  19 of the 20 patients completed the study. One patient 
with genotype 2a/2c in the IFN-α group decided to dis-
continue the study after 8 weeks of treatment due to gen-
eral weakness and fatigue. In general, both treatments 
were well tolerated and the adverse events were mild to 
moderate (Table 4). There was no clinically significant 
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Table 3. Virological Responses in the Cohort with a High 
Baseline Viral Load
IFN-β-1a IFN-α
HCV-RNA (IU/mL) HCV-RNA (IU/mL)
≤400,000
n=3 (%)
＞400,000
n=7 (%)
≤400,000
n=8 (%)
＞400,000
n=2 (%)
EVR 3 (100) 6 (85.7)  8 (100) 0 (0)
ETR 3 (100) 3 (42.9) 4 (50) 0 (0)
SVR 3 (100) 1 (14.3) 4 (50) 0 (0)
IFN-β, interferon beta; IFN-α, interferon-alpha; HCV, 
hepatitis C virus; EVR, early virological response (treatment 
week 12); ETR, end-of-treatment response (treatment week 
24); SVR, sustained virologic response (the 24-week obser-
vation phase).
Table 4. Incidence of Adverse Events during the Treatment 
Period
Adverse event
IFN-β-1a
n=10 (%)
IFN-α
n=10 (%)
General weakness 6 (60) 8 (80)
Headache 5 (50) 7 (70)
Flu-like symptom 5 (50) 2 (20)
Anorexia 4 (40) 7 (70)
Weight loss* 2 (20) 6 (60)
Fatigue 2 (20) 1 (10)
Insomnia 2 (20) 0 (0)
Granulocytopenia
†
1 (10) 1 (10)
Pruritus 1 (10) 1 (10)
Skin rash 1 (10) 1 (10)
Abdominal pain 1 (10) 0 (0)
Diarrhea 1 (10) 0 (0)
Hair loss 0 (0) 5 (50)
Oral ulcer 0 (0) 2 (20)
Dizziness 0 (0) 2 (20)
Anemia
‡
0 (0) 0 (0)
Thrombocytopenia
§
0 (0) 0 (0)
*Weight loss＞2 kg/month. 
†
WBC＜750/μL.
‡
Hgb＜10 g/dL. 
§
Platelet＜50,000/uL.
differences in the laboratory parameters between the two 
groups at all the time points. No serious adverse event 
attributed to the study treatment was reported.
DISCUSSION
  Currently, IFN-α based antiviral therapies are well-ac-
cepted and approved regimens for the treatment of chron-
ic HCV infection. Despite the modification of the IFN-α 
molecule from the conventional form to the pegylated 
form and the extension of treatment duration from 24 
weeks to 48 weeks, there is still a substantial proportion 
of patients who did not achieve a SVR.4 The outlook is 
still disappointing for the approximately 50% of patients 
with HCV genotype 1 infection. Despite the encouraging 
breakthroughs in search of the next solution for HCV in-
fection, it may still take several years before any new 
treatment can be approved for widespread use.8,22 In view 
of the situation, IFN-β appears to be an attractive alter-
native to be investigated since it too has antiviral activities 
and binds to the same IFN type 1 receptor as IFN-α.
  Although natural IFN-β has been used to treat HCV 
infection in Japan for quite a while and its virological re-
sponse is similar to IFN-α, its intravenous route of ad-
ministration is probably the main obstacle preventing it 
from becoming a treatment of choice.23,24 In an early 
study, natural IFN-β given 6 MIU 3 times a week intra-
muscularly had been compared to IFN-α in patients with 
HCV infection not responding to previous IFN-α therapy. 
The virological response was poorer in the IFN-β 
group.25 Another report looked into the use natural IFN-β 
via subcutaneous injection. In this study, 6 MIU of natu-
ral IFN-β was given subcutaneously at 3 times a week 
for 6 months. Though the response was not optimum, 
the authors suggested that a higher dose might be used 
based on the excellent tolerance.26
  Another form of IFN-β produced by recombinant DNA 
technology, recombinant IFN-β (IFN-β-1a), had been 
approved for the treatment of multiple sclerosis for nearly 
10 years.27 Habersetzer et al.19 were the first group to 
study the use of IFN-β-1a in HCV treatment. In their pi-
lot study using IFN-β-1a 3 times a week for 24 weeks, 
the low-dose arm (9 MIU) had a better outcome than the 
high-dose arm (12 MIU). Apparently, the baseline viral 
load was twice in the high-dose arm. This might contrib-
ute to the poor response in the high-dose group. The au-
thors strongly suggested further evaluation of IFN-β-1a, 
especially in combination with ribavirin, in the treatment 
of chronic HCV infection.
  Recently, two other studies using IFN-β-1a had been 
reported. Cheng et al.21 reported results of IFN-β-1a 
monotherapy in 270 patients who had HCV infection that 
was non-responsive to IFN-α therapy. Although the over-
all SVR was merely 3.4%, a sub-group analysis provided 
the interesting finding that Chinese population achieved a 
significantly higher SVR (21.7%) suggesting an ethnic fac-
tor at the work. Pellicano et al.20 were the first to report 
the use of IFN-β-1a plus ribavirin combination therapy. 
Their study, conducted in treatment-naïve Italian pop-
ulation, compared IFN-β-1a monotherapy and IFN-β-1a 
plus ribavirin combination therapy. IFN-β-1a was ad-
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ministered subcutaneously daily at 6 MIU (22 mcg) for 
24 weeks. The SVR rate obtained were 21.6% and 27.5% 
in the monotherapy and combination therapy, respec-
tively. They noted both HCV genotype and baseline viral 
load as predictive factors of response.20
　Our pilot study was the first to report IFN-β-1a ad-
ministered subcutaneously 3 times a week plus daily rib-
avirin combination therapy and compare it with IFN-α 
plus ribavirin in treatment-naïve patients with the same 
clinical setting. Our SVR results (40%) for IFN-β-1a 
combination therapy were better than that reported 
Pellicano et al.20 Although in their study, IFN-β-1a was 
given daily instead of 3 times a week, the total dosages 
and treatment duration were similar to ours. One possi-
bility of the better response seen in our study could be 
the ethnic factor suggested by Cheng et al.21 According to 
their analysis, Caucasian population seemed to response 
poorly with IFN-β-1a therapy. Such finding has also been 
observed in IFN-α therapy.28 Recently, Chan et al.29 
strongly supported the use of IFN-β-1a as an alternative 
to the IFN-α for Asian patients with chronic hepatitis C. 
The present study was more consistent with that from 
Cheng et al.21 since we would expect a much better re-
sponse from the treatment-naïve population.
  The other interesting finding in our study was the 
trend toward a better response for IFN-β-1a therapy in 
the patients with higher baseline viral load. As pointed 
out by Castro et al.26, investigation of higher doses of 
IFN-β-1a were legitimate based on its safety profile. 
Although the results from Habersetzer et al.19 may seem 
puzzling with the low-dose group giving a better re-
sponse, we believe this was probably due to the sig-
nificantly higher baseline viral load in the high-dose 
group. It is well recognized today that baseline viral load, 
especially in HCV genotype 1, is a strong predictor of 
treatment response. Our results indicated that IFN-β-1a 
combination therapy might be more effective in patients 
with high viral load as compared to IFN-α combination 
therapy. 
  In our study, IFN-β-1a group appeared to be asso-
ciated with similar adverse events in terms of frequency 
and severity when compared to IFN-α group. Although 
there was no significant difference between two groups, 
two severe adverse events (headache and general weak-
ness) were reported in the IFN-α group but none re-
ported in the IFN-β-1a group. A recent review had con-
firmed the better safety profile of IFN-β-1a in the treat-
ment of chronic HCV infection.30 High dose IFN-β-1a of 
24 MIU (88 mcg) given daily for 48 weeks had been in-
vestigated previously in HCV infected patients and the 
dosage was found to be well tolerated.21 Though IFN-α 
has an acceptable safety profile in HCV infected pop-
ulation, it does have some severe potential side effects 
and we do not foresee a higher dose of IFN-α as a viable 
option.31 In this aspect, IFN-β-1a can be a potential can-
didate in the cohort of patients who cannot tolerate IFN-
α therapy. Recently, the phase I study of pegylated IFN-
β-1a is ongoing in the patients with multiple sclerosis in 
Europe. In addition, the availability of pegylated IFN-β- 
1a in the near future may offer an alternative to the cur-
rent pegylated IFN-α therapy.32
  The limitation of this study was due to its small sam-
ple size. Thus the results of this pilot study need to be 
confirmed in a larger patient population. If the efficacy of 
IFN-β-1a could be confirmed in a larger number of pa-
tients, IFN-β- 1a would offer an alternative to the IFN-α 
therapy in patients with chronic hepatitis C. As another 
perspective, our study couldn’t elucidate the effect of the 
IFN-β-1a for HCV patients with genotype 1. In general, 
a full 48-week therapy is required of the patients infected 
with genotype 1. Therefore, it is likely that 24 weeks of 
treatment might have been insufficient for those infected 
with genotype 1.
  In conclusion, our pilot study provided IFN-β-1a com-
bination therapy might be considerably advantageous for 
patients with chronic hepatitis C in terms of efficacy as 
well as safety. A larger comparative study is needed to 
confirm these encouraging findings especially in Asian 
populations. 
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